You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 3, 2025

CLINICAL TRIALS PROFILE FOR PHENOXYBENZAMINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for phenoxybenzamine hydrochloride

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00770705 ↗ Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery Withdrawn Vanderbilt University Phase 2 2008-10-01 Phenoxybenzamine, an irreversible alpha-adrenergic blocker, may prove beneficial to infants and children with congenital heart disease undergoing open cardiac repair, due to a theoretic benefits of a uniform and smooth reduction in systemic vascular resistance in the perioperative period. Vasodilation allows for low pressure, high flow systemic perfusion while on cardiopulmonary bypass. Support for the use of phenoxybenzamine in humans has been documented in several studies involving the perioperative management of both adults and children requiring cardiopulmonary bypass, and in management of patients with pheochromocytoma. 1-7 Phenoxybenzamine has been associated with more uniform body cooling and rewarming, and improved tissue perfusion during bypass.8 It is also known to increase cardiac output, stroke volume, and renal blood flow when given intravenously. 9 Specifically in pediatric open heart surgery, the combined use of phenoxybenzamine and dopamine provided a stable hemodynamic condition without a high total peripheral vascular resistance and stimulated postoperative diuresis. 9 Afterload reduction with parenteral phenoxybenzamine in neonates undergoing the Norwood procedure for hypoplastic left heart syndrome is associated with improved systemic oxygen delivery and stabilization of systemic vascular resistance.10 Furthermore, a strategy of reducing afterload with phenoxybenzamine and stabilizing the pulmonary to systemic flow ratio in this select population of patients has also been shown to improve operative survival. 11 We hypothesize that phenoxybenzamine will reduce afterload on the systemic ventricle in our selected patient population, thereby improving ventricular performance and decreasing the risks of pulmonary to systemic flow imbalance associated with current short-acting vasodilator therapy. We will plan to evaluate both physiologic variables as well as surgical outcomes in the selected study population.
NCT00620945 ↗ Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-pulmonary Bypass Terminated The Cleveland Clinic N/A 2006-06-01 Cardiopulmonary bypass [CPB] in small size bodies can result in decreased peripheral perfusion. This results in anaerobic metabolism as evidenced by lactic acidosis. High flow perfusion results in systemic hypertension which is accentuated by moderate hypothermia commonly used during cardiopulmonary bypass. Phenoxybenzamine [PBZ] is an arteriolar vasodilator that acts by irreversibly blocking the alpha adrenergic receptors. It causes vasodilatation allowing high flow, low pressure CPB. It has been used extensively outside US in Canada, Europe and Australia. In the US oral PBZ is FDA approved, whereas intravenous PBZ is only available as an investigational drug
NCT00590018 ↗ Corticosteroids in Postoperative Critically Ill Neonates With Low Cardiac Output Syndrome With Congenital Heart Disease Completed Baylor College of Medicine Phase 2 2003-02-01 Babies having heart surgery often have problems after surgery with their blood pressure and getting enough blood to their bodies. To treat this they require medicines to keep their blood pressure high enough to get blood to their bodies. The side effects of these medicines include fast heart rates and increasing the amount of work the heart has to do. Corticosteroids are made by the body and help to use the energy in the food people eat, control the chemicals in their blood and maintain their blood pressure. Corticosteroids made by the body may be decreased in patients that have major surgery. Corticosteroids help to increase blood pressure and can decrease the amount of blood pressure medicines a patient requires. Corticosteroids have been shown to increase blood pressure in patients with bacterial infections and in very small, premature babies but have only been studied in a few babies who have had heart surgery. The way corticosteroids work is unknown but may involve decreasing the body's response to being on a heart-lung machine or give steroids not being made by the patient. Corticosteroids have been shown to be helpful in treating many diseases. The purpose of this study is to look at the effects of corticosteroids in babies who have had heart surgery and need blood pressure medicines in the intensive care unit after surgery. Our idea is that getting corticosteroids will allow us to decrease the amount of blood pressure medicines each patient needs and improve how they do after surgery. We also plan to do blood tests to help determine how the corticosteroids are working. It will be randomly determined if the subject receives corticosteroids or salt water. The subject will receive a corticosteroid or salt water once a day for five days. Their vital signs will be monitored, especially blood pressure and their need for medicines to increase their blood pressure. Blood work will also be obtained to determine their body's ability to make steroids.
NCT00569855 ↗ Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery Completed Arkansas Children's Hospital Research Institute Phase 2 2001-02-01 Cardiopulmonary bypass is done with a machine that does the work of the heart and lungs during open-heart surgery. This study is to determine if intravenous (i.v.) phenoxybenzamine is safe. This drug lowers the blood pressure, making it easier for the cardiopulmonary bypass machine to deliver blood and oxygen to all of the organs and tissues.
NCT00569855 ↗ Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery Completed University of Arkansas Phase 2 2001-02-01 Cardiopulmonary bypass is done with a machine that does the work of the heart and lungs during open-heart surgery. This study is to determine if intravenous (i.v.) phenoxybenzamine is safe. This drug lowers the blood pressure, making it easier for the cardiopulmonary bypass machine to deliver blood and oxygen to all of the organs and tissues.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 5 of 5 entries

Clinical Trial Conditions for phenoxybenzamine hydrochloride

Condition Name

3221000.511.522.53PheochromocytomaParagangliomaCardiopulmonary BypassAdrenalectomy; Status[disabled in preview]
Condition Name for phenoxybenzamine hydrochloride
Intervention Trials
Pheochromocytoma 3
Paraganglioma 2
Cardiopulmonary Bypass 2
Adrenalectomy; Status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

3222000.511.522.53PheochromocytomaHeart DiseasesHeart Defects, CongenitalParaganglioma[disabled in preview]
Condition MeSH for phenoxybenzamine hydrochloride
Intervention Trials
Pheochromocytoma 3
Heart Diseases 2
Heart Defects, Congenital 2
Paraganglioma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for phenoxybenzamine hydrochloride

Trials by Country

+
Trials by Country for phenoxybenzamine hydrochloride
Location Trials
United States 5
Netherlands 1
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for phenoxybenzamine hydrochloride
Location Trials
California 1
Tennessee 1
Ohio 1
Texas 1
Arkansas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for phenoxybenzamine hydrochloride

Clinical Trial Phase

28.6%14.3%42.9%14.3%00.811.21.41.61.822.22.42.62.833.2Phase 4Phase 3Phase 2[disabled in preview]
Clinical Trial Phase for phenoxybenzamine hydrochloride
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

42.9%28.6%14.3%14.3%00.811.21.41.61.822.22.42.62.833.2CompletedRecruitingWithdrawn[disabled in preview]
Clinical Trial Status for phenoxybenzamine hydrochloride
Clinical Trial Phase Trials
Completed 3
Recruiting 2
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for phenoxybenzamine hydrochloride

Sponsor Name

trials000111112222Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)St. Antonius HospitalAtrium Medical Center[disabled in preview]
Sponsor Name for phenoxybenzamine hydrochloride
Sponsor Trials
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 1
St. Antonius Hospital 1
Atrium Medical Center 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

100.0%0-2024681012141618202224Other[disabled in preview]
Sponsor Type for phenoxybenzamine hydrochloride
Sponsor Trials
Other 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Phenoxybenzamine Hydrochloride: Clinical Trials, Market Analysis, and Projections

Introduction

Phenoxybenzamine hydrochloride is a potent alpha-adrenergic antagonist used primarily in the management of pheochromocytoma, a rare tumor of the adrenal gland, as well as in treating episodes of hypertension and sweating associated with this condition. Here, we will delve into the current state of clinical trials, market analysis, and future projections for this drug.

Clinical Trials and Usage

Current Clinical Use

Phenoxybenzamine hydrochloride is indicated for the control of episodes of hypertension and sweating in patients with pheochromocytoma. It works by blocking alpha receptors, leading to the relaxation of blood vessel muscles and a subsequent lowering of blood pressure[1][3][4].

Clinical Trials

Several clinical trials and studies have been conducted to evaluate the efficacy and safety of phenoxybenzamine hydrochloride. A systematic review involving 14 studies from 2011 to 2018 showed that phenoxybenzamine was administered intravenously in doses ranging from 10-100 mg/day for durations of 7 days to 10 weeks. These studies highlighted improvements in patient outcomes, particularly in managing blood pressure and reducing cardiovascular complications during surgical resections of pheochromocytoma[3].

Ongoing and Future Trials

While specific ongoing clinical trials for phenoxybenzamine hydrochloride are not detailed in the available sources, the continuous need for effective treatments in rare diseases like pheochromocytoma suggests that research and clinical trials will continue. Future trials may focus on optimizing dosages, exploring combination therapies, and expanding the drug's use to other conditions.

Market Analysis

Market Size and Growth

The phenoxybenzamine hydrochloride market has witnessed significant growth in recent years and is projected to continue this trend. The market is expected to expand substantially from 2023 to 2031, driven by increasing prevalence of hypertension and pheochromocytoma, government initiatives for rare disease research, and collaborative efforts between healthcare providers and pharmaceutical companies[2][5].

Market Segmentation

The market is segmented based on type (99% purity and other), application (tablets, injections), and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa). This segmentation helps in understanding the diverse market dynamics and identifying growth opportunities in different sectors[2][5].

Market Drivers

Key drivers of the phenoxybenzamine hydrochloride market include:

  • Growing Prevalence of Conditions: Increasing cases of hypertension and pheochromocytoma necessitate targeted treatments.
  • Government Initiatives: Funding for rare disease research and drug affordability programs support market growth.
  • Collaborative Efforts: Healthcare providers and pharmaceutical companies work together to enhance patient education and awareness[5].

Market Restraints and Challenges

Despite the positive outlook, the market faces several challenges:

  • Economic and Regulatory Challenges: Assessing economic, regulatory, and competitive challenges impacts market penetration.
  • Limited Market Penetration: Understanding the reasons behind limited market penetration is crucial for strategic planning.
  • Patent Expiration: The impact of patent expiration on exclusivity and market share retention is a significant concern[5].

Market Projections

Future Growth Prospects

The phenoxybenzamine hydrochloride market is poised for significant growth from 2023 to 2031. Projections indicate sustained and substantial expansion, driven by the increasing demand for effective treatments for rare diseases and the ongoing efforts to enhance patient care and education[2][5].

Market Opportunities

Several opportunities exist to further grow the market:

  • Data-Driven Marketing: Utilizing data-driven insights to tailor marketing campaigns can increase market penetration.
  • Strategic Pricing: Implementing strategic pricing strategies can help expand the market.
  • Collaboration with Health Organizations: Collaborating with health organizations to raise awareness about phenoxybenzamine in niche medical fields can also drive growth[5].

Competitive Landscape

The competitive landscape of the phenoxybenzamine hydrochloride market involves a detailed analysis of market share, strategic approaches, product range, certifications, regulatory approvals, and technological developments among leading market players. This analysis is crucial for understanding the market dynamics and identifying potential competitors and partners[5].

Key Takeaways

  • Clinical Trials: Phenoxybenzamine hydrochloride has shown efficacy in managing pheochromocytoma and hypertension in clinical trials.
  • Market Growth: The market is expected to grow significantly from 2023 to 2031, driven by increasing demand and supportive government initiatives.
  • Market Segmentation: The market is segmented by type, application, and geographical regions, each presenting unique growth opportunities.
  • Challenges and Opportunities: Despite challenges like patent expiration and limited market penetration, there are opportunities for growth through data-driven marketing and collaboration with health organizations.

FAQs

What is the primary use of phenoxybenzamine hydrochloride?

Phenoxybenzamine hydrochloride is primarily used to treat pheochromocytoma and episodes of hypertension and sweating associated with this condition.

What is the mechanism of action of phenoxybenzamine hydrochloride?

Phenoxybenzamine hydrochloride works by blocking alpha receptors, leading to the relaxation of blood vessel muscles and a subsequent lowering of blood pressure.

What are the key drivers of the phenoxybenzamine hydrochloride market?

Key drivers include the growing prevalence of hypertension and pheochromocytoma, government initiatives for rare disease research, and collaborative efforts between healthcare providers and pharmaceutical companies.

What challenges does the phenoxybenzamine hydrochloride market face?

The market faces challenges such as economic and regulatory hurdles, limited market penetration, and the impact of patent expiration on exclusivity and market share retention.

What are the future growth prospects for the phenoxybenzamine hydrochloride market?

The market is projected to experience significant growth from 2023 to 2031, driven by increasing demand and supportive initiatives.

Sources

  1. DrugBank: Phenoxybenzamine: Uses, Interactions, Mechanism of Action.
  2. Market Research Intellect: Global Phenoxybenzamine Hydrochloride Market Size, Trends and ...
  3. University of Maryland, Baltimore: Phenoxybenzamine hydrochloride.
  4. Patsnap: Phenoxybenzamine Hydrochloride - Drug Targets, Indications, Patents.
  5. 360 Research Reports: Phenoxybenzamine Hydrochloride Tablets Market Size 2025-2030.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.